employee’s principal residence or principal place of employment at the time of the disaster was located in an area designated by FEMA for individual assistance with respect to the disaster, are eligible for withdrawal.
Upon the death of a participant, vested balances are paid to the designated beneficiary, or if no beneficiary has been designated, the balance is paid according to the terms and conditions of the Plan. The beneficiary has the option to take the Medtronic plc ordinary shares in-kind or as cash. Any fraction of a share of stock is paid in cash.
Notes Receivable from Participants
Participants may have two outstanding notes at a time, as described below, and are able to borrow up to 50% of their vested account balance in the participant’s 401(k) Component/ESOP accounts not to exceed the maximum note amount of $50. The notes may only be distributed from the participant's 401(k) Component/ESOP balance. The minimum note amount is $1. Participants are limited to one general purpose note and one primary residence note outstanding at a time. Notes are repaid through payroll deductions in equal amounts, typically over one to five years for a general purpose note or 15 years for a primary residence note. The notes are collateralized by the balance in the participant’s account. The interest rate on new loans is calculated as one percentage point above the prime rate as reported by Reuters on the 15th date of the month prior to the first day of the month to which it is to apply. At April 30, 2024, notes receivable from participants were due at various dates through March 2029, with interest rates ranging from 3.25% to 9.50%. At April 30, 2023, notes receivables from participants were due at various dates through April 2038, with interest rates ranging from 3.25% to 9.25%.
Contract termination occurs whenever the contract value or market value of the covered investments reaches zero or upon certain events of default. If the contract terminates due to issuer default, the issuer will generally be required to pay to the Plan the excess, if any, of contract value over market value on the date of termination. If the contract terminates when the market value equals zero, the issuer will pay the excess of contract value over market value to the Plan to the extent necessary for the Plan to satisfy outstanding contract value withdrawal requests. Contract termination also may occur by either party upon election and notice.
某些事件限制了計劃與保險公司和金融機構發行人以合同價值交易的能力。這些事件包括以下情況: (i) 對計劃文件的修訂(包括完全或部分計劃終止或與其他計劃合併); (ii) 對計劃中禁用競爭投資選項的修改或股權洗滌條款的刪除; (iii) 計劃贊助方破產或其他計劃贊助方事件(例如,剝離或分拆子公司),導致計劃出現重大提款;或 (iv) 信託未能獲得聯邦所得稅豁免或根據ERISA所需的任何被禁止交易豁免。計劃管理員不相信任何此類事件的發生會限制計劃與參與者以合同價值交易的能力。
Net appreciation and investment income in the Medtronic, Inc. Master Trust Fund net assets is as follows:
Year Ended
(in thousands)
April 30, 2024
Investment income:
Net appreciation in fair value of investments
$
1,252,594
Dividends on Medtronic plc ordinary shares
16,128
Interest and dividends
539
Total investment gain, net
$
1,269,261
The net appreciation in the fair value of the Master Trust investments for the year ended April 30, 2024, includes gains and losses on investments purchased and sold, as well as unrealized gains and losses on those held during the year, related to all investments reported at fair value above. The Medtronic Capital Preservation Fund is reported at contract value. See Note 3 for further information regarding fair value measurements.
5. Related Party Transactions and Party-In-Interest Transactions
The Plan’s investments consist of the Plan's interest in the Master Trust, which includes Company ordinary shares, a self-directed brokerage option, and managed accounts comprised of collective trusts, mutual funds, and fully benefit-responsive investment contracts. Certain investment transactions were managed by the Trustee and an affiliate of the Recordkeeper during the year ended April 30, 2024. These transactions are allowed by the Plan and the IRC and qualify as party-in-interest transactions, which are exempt from the prohibited transactions rules. In addition, as previously noted, the Master Trust invests in the ordinary shares of Medtronic plc. During the year ended April 30, 2024, the Master Trust made purchases of $12,346 and sales of $69,344 of the Company's ordinary shares. The Plan's investment in ordinary shares of Medtronic plc at April 30, 2024 and 2023 was $464,350, and $587,678, respectively.
At April 30, 2024 and 2023, the Plan had notes receivable from participants of $94,641 and $90,109, respectively. These transactions qualify as party-in-interest transactions, which are exempt from prohibited transaction rules.
6. Tax Status
The Plan received a favorable determination letter, effective October 22, 2014, from the Internal Revenue Service (IRS). The IRS has determined that the Plan and the related trust are designed in accordance with the applicable sections of the IRC and are, therefore, exempt from income taxes. Although the Plan document that the IRS reviewed in issuing its most recent determination letter has since been amended and restated, the Plan Administrator believes that the Plan is currently designed
15
and being operated in compliance with the applicable requirements of the IRC. Therefore, no provision for income taxes has been included in the Plan’s financial statements.
U.S. GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan has not recognized any interest or penalties related to uncertain tax positions. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Plan administrator believes it is no longer subject to income tax examinations for the years prior to 2020.
7. Reconciliation of Financial Statements to Form 5500
The following is a reconciliation of net assets available for benefits on the financial statements to the Form 5500 as of April 30, 2024:
April 30
2024
2023
Net assets available for benefits on the financial statements
$
12,933,137
$
12,199,435
Deemed loans with no post-default payments
(1,159)
(1,140)
Net assets available for benefits on Form 5500
$
12,931,979
$
12,198,295
The following is a reconciliation of the net increase in net assets available for benefits on the financial statements to the Form 5500 for the year ended April 30, 2024:
April 30, 2024
Net increase in net assets available for benefits on the financial statements
$
733,702
Deemed loans with no post-default payments
(19)
Net increase in net assets available for benefits on Form 5500
$
733,683
8. Subsequent Events
Subsequent events have been evaluated through October 24, 2024, the date this report was issued. There have been no significant subsequent events to report.
16
SUPPLEMENTAL SCHEDULE
17
Supplemental Schedule Required by ERISA
Medtronic Savings and Investment Plan
Schedule H, Line 4i – Schedule of Assets (Held at End of Year)
April 30, 2024
EIN 41-0793183
Plan Number 005
(in thousands)
Identity of Issue, Borrower, Lessor or Similar Party
Description of Investment, Including Maturity Date, Rate of Interest, Collateral, Par or Maturity Value
Cost
Current Value
*
Plan's interest in Medtronic, Inc. Master Trust Fund
**
$
12,608,729
*
Notes receivable from participants
Interest at 3.25% to 9.50%
$—
93,482
$
12,702,211
*
Denotes party-in-interest
**
Cost information is excluded, as it is not required for participant directed investments.